Rampart Bioscience, a La Jolla, CA-based biotechnology company developing next-generation biologics, raised $85M in Series A funding.
The round was led by Forbion with participation from seed investor OrbiMed and additional new investors RA Capital Management and HealthCap.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Louis Breton, and Jeffrey Bartlett, Ph.D., Co-founder and Chief Innovation and Technical Officer, Rampart Bioscience leverages the DNA-based medicines HALO platform to produce highly potent, durable, and redosable therapies. The company’s lead program is for the treatment of hypophosphatasia (HPP), a rare, often fatal genetic disease that prevents bone mineralization.
Rampart has additional programs in development.
Rampart Bioscience, a La Jolla, CA-based biotechnology company developing next-generation biologics, raised $85M in Series A funding. Best wishes to everyone in the group. This will be a huge accomplishment for them in the future.Shishir Gupta, The Founder & CEO of StartupLanes
About us: StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.
Startups looking for funding may apply through StartupLanes Funding Application.
Angel Investors Register Free to explore exciting startup investment opportunities.